背景:运动强度(例如,目标心率[HR])是运动处方的基本组成部分,可为癌症幸存者带来健康益处。尽管胸部佩戴的监视器有效,它们在社区和无监督运动环境中的可行性可能具有挑战性。随着可穿戴技术的不断改进,基于消费者的可穿戴传感器可能代表传统监测的可访问替代方案,提供额外的优势。
目的:这项研究的目的是检查PolarH10胸部监测仪和FitbitInspireHR之间的一致性,以测量随机干预组的乳腺癌幸存者的HR,飞行员演习试验。
方法:参与者包括随机参加12周有氧运动项目的乳腺癌幸存者(N=14;年龄38-72岁)。这个节目包括三个60分钟,每周中等强度的步行训练,无论是小组或一对一,由认证的运动生理学家协助,并在当地社区健身中心举行。按照最初的设计,运动处方包括在健身中心进行的36次监督训练.然而,由于COVID-19大流行,监督会话的数量取决于参与者是在2020年3月之前还是之后注册。在每次练习期间,通过PolarH10胸部监护仪和手腕佩戴的FitbitInspireHR在5个阶段同时测量HR(以每分钟节拍为单位):运动前休息;热身中点;运动过程中点;冷静下来的中点;和运动后恢复。运动生理学家在每个阶段的中点从每个设备记录参与者的HR。PolarH10和FitbitInspireHR之间的HR一致性使用Lin一致性相关系数(rc)进行评估,CI为95%。Linrc的范围从0到1.00,0表示不一致,1.00表示完全一致。计算相对错误率以检查运动阶段之间的差异。
结果:可获得样本中200个监督会话的数据(每位参与者的会话:平均值13.33,SD13.7)。到练习阶段,PolarH10监测仪和Fitbit之间的一致性在运动前坐姿休息(rc=0.76,95%CI0.70-0.81)和运动后坐姿恢复(rc=0.89,95%CI0.86-0.92)期间最高,其次是运动的中点(rc=0.63,95%CI0.55-0.70)和降温(rc=0.68,95%CI0.60-0.74)。热身期间的一致性最低(rc=0.39,95%CI0.27-0.49)。相对错误率范围为-3.91%至3.09%,在热身期间最大(相对错误率:平均值-3.91,SD11.92%)。
结论:Fitbit高估了运动强度峰值时的HR,构成过度膨胀的风险,这对乳腺癌幸存者的健康水平可能不安全。虽然FitbitInspireHR可用于估计运动HR,在考虑参与者安全和数据解释时,需要采取预防措施。
背景:Clinicaltrials.govNCT03980626;https://clinicaltrials.gov/study/NCT03980626?term=NCT03980626&rank=1.
BACKGROUND: Exercise intensity (eg, target heart rate [HR]) is a fundamental component of exercise prescription to elicit health benefits in cancer survivors. Despite the validity of chest-worn monitors, their feasibility in community and unsupervised exercise settings may be challenging. As wearable technology continues to improve, consumer-based wearable sensors may represent an accessible alternative to traditional monitoring, offering additional advantages.
OBJECTIVE: The purpose of this study was to examine the agreement between the Polar H10 chest monitor and Fitbit Inspire HR for HR measurement in breast cancer survivors enrolled in the intervention arm of a randomized, pilot exercise trial.
METHODS: Participants included breast cancer survivors (N=14; aged 38-72 years) randomized to a 12-week aerobic exercise program. This program consisted of three 60-minute, moderate-intensity walking sessions per week, either in small groups or one-on-one, facilitated by a certified exercise physiologist and held at local community fitness centers. As originally designed, the exercise prescription included 36 supervised sessions at a fitness center. However, due to the COVID-19 pandemic, the number of supervised sessions varied depending on whether participants enrolled before or after March 2020. During each exercise session, HR (in beats per minute) was concurrently measured via a Polar H10 chest monitor and a wrist-worn Fitbit Inspire HR at 5 stages: pre-exercise rest; midpoint of warm-up; midpoint of exercise session; midpoint of cool-down; and postexercise recovery. The exercise physiologist recorded the participant\'s HR from each device at the midpoint of each stage. HR agreement between the Polar H10 and Fitbit Inspire HR was assessed using Lin concordance correlation coefficient (rc) with a 95% CI. Lin rc ranges from 0 to 1.00, with 0 indicating no concordance and 1.00 indicating perfect concordance. Relative error rates were calculated to examine differences across exercise session stages.
RESULTS: Data were available for 200 supervised sessions across the sample (session per participant: mean 13.33, SD 13.7). By exercise session stage, agreement between the Polar H10 monitor and the Fitbit was highest during pre-exercise seated rest (rc=0.76, 95% CI 0.70-0.81) and postexercise seated recovery (rc=0.89, 95% CI 0.86-0.92), followed by the midpoint of exercise (rc=0.63, 95% CI 0.55-0.70) and cool-down (rc=0.68, 95% CI 0.60-0.74). The agreement was lowest during warm-up (rc=0.39, 95% CI 0.27-0.49). Relative error rates ranged from -3.91% to 3.09% and were greatest during warm-up (relative error rate: mean -3.91, SD 11.92%).
CONCLUSIONS: The Fitbit overestimated HR during peak exercise intensity, posing risks for overexercising, which may not be safe for breast cancer survivors\' fitness levels. While the Fitbit Inspire HR may be used to estimate exercise HR, precautions are needed when considering participant safety and data interpretation.
BACKGROUND: Clinicaltrials.gov NCT03980626; https://clinicaltrials.gov/study/NCT03980626?term=NCT03980626&rank=1.